Alexion Pharmaceuticals Inc Valuation – February 2019 $ALXN

Company Profile (excerpt from Reuters): Alexion Pharmaceuticals, Inc., incorporated on January 28, 1992, is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).


Downloadable PDF version of this valuation:

ModernGraham Valuation of ALXN – February 2019

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $28,604,032,000 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 2.88 Pass
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Fail
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 314.76% Pass
6. Moderate PEmg Ratio PEmg < 20 34.23 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 3.15 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 2.88 Pass
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 1.13 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Fail
5. Earnings Growth EPSmg greater than 5 years ago Pass


Stage 2: Determination of Intrinsic Value

EPSmg $3.74
MG Growth Estimate 15.00%
MG Value $143.99
Opinion Fairly Valued
MG Grade D+
MG Value based on 3% Growth $54.23
MG Value based on 0% Growth $31.79
Market Implied Growth Rate 12.86%
Current Price $128.02
% of Intrinsic Value 88.91%

Alexion Pharmaceuticals, Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PEmg and PB ratios. The Enterprising Investor has concerns regarding the level of debt relative to the net current assets, and the lack of dividends. As a result, all value investors following the ModernGraham approach should explore other opportunities at this time or proceed cautiously with a speculative attitude.

As for a valuation, the company appears to be Fairly Valued after growing its EPSmg (normalized earnings) from $1.58 in 2015 to an estimated $3.74 for 2019. This level of demonstrated earnings growth supports the market’s implied estimate of 12.86% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value within a margin of safety relative to the price.

At the time of valuation, further research into Alexion Pharmaceuticals, Inc. revealed the company was trading above its Graham Number of $90.72. The company does not pay a dividend. Its PEmg (price over earnings per share – ModernGraham) was 34.23, which was below the industry average of 39.51, which by some methods of valuation makes it one of the most undervalued stocks in its industry. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-6.13.

Alexion Pharmaceuticals, Inc. scores quite poorly in the ModernGraham grading system, with an overall grade of D+.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$6.13
Graham Number $90.72
PEmg 34.23
Current Ratio 2.88
PB Ratio 3.15
Current Dividend $0.00
Dividend Yield 0.00%
Number of Consecutive Years of Dividend Growth 0

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 12/1/2018
Total Current Assets $3,385,000,000
Total Current Liabilities $1,174,000,000
Long-Term Debt $2,501,700,000
Total Assets $13,931,900,000
Intangible Assets $8,678,700,000
Total Liabilities $4,766,600,000
Shares Outstanding (Diluted Average) 225,400,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $8.92
Dec2018 $0.35
Dec2017 $1.97
Dec2016 $1.76
Dec2015 $0.67
Dec2014 $3.26
Dec2013 $1.27
Dec2012 $1.28
Dec2011 $0.91
Dec2010 $0.52
Dec2009 $1.63
Dec2008 $0.20
Dec2007 -$0.64
Dec2006 -$1.04
Jul2005 -$0.98
Jul2004 -$0.86
Jul2003 -$1.16
Jul2002 -$0.78
Jul2001 -$0.82
Jul2000 -$0.36
Jul1999 -$0.14

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $3.74
Dec2018 $1.30
Dec2017 $1.78
Dec2016 $1.67
Dec2015 $1.58
Dec2014 $1.84
Dec2013 $1.12
Dec2012 $1.00
Dec2011 $0.75
Dec2010 $0.49
Dec2009 $0.26
Dec2008 -$0.50
Dec2007 -$0.88
Dec2006 -$0.98
Jul2005 -$0.94
Jul2004 -$0.88
Jul2003 -$0.82

Recommended Reading:

Other ModernGraham posts about the company

Alexion Pharmaceuticals Inc Valuation – April 2018 $ALXN
Alexion Pharmaceuticals Inc Valuation – December 2016 $ALXN
Alexion Pharmaceuticals Inc. Analysis – August 2015 Update $ALXN
47 Companies in the Spotlight This Week – 5/16/15
Alexion Pharmaceuticals Quarterly Valuation – May 2015 $ALXN

Other ModernGraham posts about related companies

Vertex Pharmaceuticals Inc Valuation – February 2019 $VRTX
Perrigo Company Valuation – February 2019 $PRGO
Eli Lilly and Co Valuation – January 2019 $LLY
Zoetis Inc Valuation – January 2019 $ZTS
Gilead Sciences Inc Valuation – January 2019 $GILD
Pfizer Inc Valuation – November 2018 $PFE
Nektar Therapeutics Valuation – November 2018 $NKTR
Merck & Co Inc Valuation – November 2018 $MRK
Ligand Pharmaceuticals Inc Valuation – September 2018 $LGND
Supernus Pharmaceuticals Inc Valuation – August 2018 $SUPN


The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.